218 USD
-0.7 (-0.32%)
219 USD
+1 (+0.46%)
We assign a fundamental rating of 6 out of 10 to KRYS. KRYS was compared to 533 industry peers in the Biotechnology industry. KRYS has an excellent financial health rating, but there are some minor concerns on its profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on KRYS. These ratings could make KRYS a good candidate for value investing.
1. Profitability
1.1 Basic Checks
KRYS had positive earnings in the past year.
In the past year KRYS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.
KRYS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 16.04%, KRYS belongs to the best of the industry, outperforming 95.69% of the companies in the same industry.
Looking at the Return On Equity, with a value of 17.48%, KRYS belongs to the top of the industry, outperforming 95.32% of the companies in the same industry.
KRYS has a better Return On Invested Capital (12.28%) than 94.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 17.48% | ||
| ROIC | 12.28% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KRYS has a Profit Margin of 53.30%. This is amongst the best in the industry. KRYS outperforms 98.69% of its industry peers.
The Operating Margin of KRYS (42.40%) is better than 99.25% of its industry peers.
With an excellent Gross Margin value of 94.26%, KRYS belongs to the best of the industry, outperforming 93.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.4% | ||
| PM (TTM) | 53.3% | ||
| GM | 94.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so KRYS is still creating some value.
The number of shares outstanding for KRYS has been increased compared to 1 year ago.
KRYS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 38.61 indicates that KRYS is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 38.61, KRYS belongs to the top of the industry, outperforming 95.69% of the companies in the same industry.
KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 38.61 |
ROIC/WACC1.42
WACC8.66%
2.3 Liquidity
A Current Ratio of 10.14 indicates that KRYS has no problem at all paying its short term obligations.
KRYS has a better Current ratio (10.14) than 81.09% of its industry peers.
KRYS has a Quick Ratio of 9.73. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
KRYS's Quick ratio of 9.73 is amongst the best of the industry. KRYS outperforms 80.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.14 | ||
| Quick Ratio | 9.73 |
3. Growth
3.1 Past
KRYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 276.84%, which is quite impressive.
KRYS shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.51%.
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
3.2 Future
The Earnings Per Share is expected to grow by 58.10% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 31.67% on average over the next years. This is a very strong growth
EPS Next Y70.36%
EPS Next 2Y62.16%
EPS Next 3Y55.07%
EPS Next 5Y58.1%
Revenue Next Year32.01%
Revenue Next 2Y39.8%
Revenue Next 3Y41.2%
Revenue Next 5Y31.67%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 32.68, which means the current valuation is very expensive for KRYS.
KRYS's Price/Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 92.13% of the companies in the same industry.
When comparing the Price/Earnings ratio of KRYS to the average of the S&P500 Index (26.31), we can say KRYS is valued slightly more expensively.
With a Price/Forward Earnings ratio of 27.73, KRYS can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, KRYS is valued cheaper than 91.76% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of KRYS to the average of the S&P500 Index (36.59), we can say KRYS is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.68 | ||
| Fwd PE | 27.73 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KRYS indicates a rather cheap valuation: KRYS is cheaper than 91.95% of the companies listed in the same industry.
KRYS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. KRYS is cheaper than 92.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.18 | ||
| EV/EBITDA | 32.18 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
KRYS has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as KRYS's earnings are expected to grow with 55.07% in the coming years.
PEG (NY)0.46
PEG (5Y)N/A
EPS Next 2Y62.16%
EPS Next 3Y55.07%
5. Dividend
5.1 Amount
No dividends for KRYS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
218
-0.7 (-0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.05%
Inst Owner Change2.8%
Ins Owners11.86%
Ins Owner Change-1.19%
Market Cap6.32B
Revenue(TTM)373.16M
Net Income(TTM)198.91M
Analysts84.44
Price Target226.9 (4.08%)
Short Float %11.62%
Short Ratio8.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.19%
Min EPS beat(2)12.14%
Max EPS beat(2)140.23%
EPS beat(4)3
Avg EPS beat(4)41.54%
Min EPS beat(4)-13.89%
Max EPS beat(4)140.23%
EPS beat(8)4
Avg EPS beat(8)30.53%
EPS beat(12)5
Avg EPS beat(12)2.39%
EPS beat(16)7
Avg EPS beat(16)0.53%
Revenue beat(2)2
Avg Revenue beat(2)2.66%
Min Revenue beat(2)2.42%
Max Revenue beat(2)2.89%
Revenue beat(4)2
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.89%
Revenue beat(8)4
Avg Revenue beat(8)4.55%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.08%
PT rev (3m)7.94%
EPS NQ rev (1m)1.24%
EPS NQ rev (3m)-0.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0.63%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)0.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.68 | ||
| Fwd PE | 27.73 | ||
| P/S | 16.94 | ||
| P/FCF | 38.18 | ||
| P/OCF | 35.88 | ||
| P/B | 5.56 | ||
| P/tB | 5.56 | ||
| EV/EBITDA | 32.18 |
EPS(TTM)6.67
EY3.06%
EPS(NY)7.86
Fwd EY3.61%
FCF(TTM)5.71
FCFY2.62%
OCF(TTM)6.08
OCFY2.79%
SpS12.87
BVpS39.24
TBVpS39.24
PEG (NY)0.46
PEG (5Y)N/A
Graham Number76.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 17.48% | ||
| ROCE | 13.77% | ||
| ROIC | 12.28% | ||
| ROICexc | 33.76% | ||
| ROICexgc | 33.76% | ||
| OM | 42.4% | ||
| PM (TTM) | 53.3% | ||
| GM | 94.26% | ||
| FCFM | 44.37% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 213.54% | ||
| Cap/Sales | 2.84% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 107.96% | ||
| Profit Quality | 83.25% | ||
| Current Ratio | 10.14 | ||
| Quick Ratio | 9.73 | ||
| Altman-Z | 38.61 |
F-Score7
WACC8.66%
ROIC/WACC1.42
Cap/Depr(3y)537.2%
Cap/Depr(5y)976.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
EPS Next Y70.36%
EPS Next 2Y62.16%
EPS Next 3Y55.07%
EPS Next 5Y58.1%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
Revenue Next Year32.01%
Revenue Next 2Y39.8%
Revenue Next 3Y41.2%
Revenue Next 5Y31.67%
EBIT growth 1Y143.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year149.9%
EBIT Next 3Y73.68%
EBIT Next 5YN/A
FCF growth 1Y239.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y269.59%
OCF growth 3YN/A
OCF growth 5YN/A
KRYSTAL BIOTECH INC / KRYS FAQ
Can you provide the ChartMill fundamental rating for KRYSTAL BIOTECH INC?
ChartMill assigns a fundamental rating of 6 / 10 to KRYS.
What is the valuation status of KRYSTAL BIOTECH INC (KRYS) stock?
ChartMill assigns a valuation rating of 7 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Undervalued.
What is the profitability of KRYS stock?
KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.
What is the financial health of KRYSTAL BIOTECH INC (KRYS) stock?
The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 9 / 10.